Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tetrahydrobiopterin increases myocardial blood flow in healthy volunteers:a double-blind, placebo-controlled study
Autore:
Walter, R; Kaufmann, PA; Buck, A; Berthold, T; Wyss, C; von Schulthess, GK; Schaffner, A; Schoedon, G;
Indirizzi:
Univ Zurich Hosp, Med Clin Res Unit B, Dept Med, CH-8091 Zurich, Switzerland Univ Zurich Hosp Zurich Switzerland CH-8091 CH-8091 Zurich, Switzerland Univ Zurich Hosp, Med Clin Res Unit B, Div Nucl Med, Dept Radiol, CH-8091 Zurich, Switzerland Univ Zurich Hosp Zurich Switzerland CH-8091 CH-8091 Zurich, Switzerland
Titolo Testata:
SWISS MEDICAL WEEKLY
fascicolo: 7-8, volume: 131, anno: 2001,
pagine: 91 - 94
SICI:
1424-7860(20010224)131:7-8<91:TIMBFI>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
NITRIC-OXIDE SYNTHASE; IMPROVES ENDOTHELIAL FUNCTION; CORONARY-ARTERY DISEASE; COFACTOR TETRAHYDROBIOPTERIN; DYSFUNCTION; ATHEROSCLEROSIS; PET; VASODILATION; INHIBITION; SUBSTRATE;
Keywords:
athersclerosis; endothelium; heart diseases; myocardium; nitric oxide; tetrahydrobiopterin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Schoedon, G Univ Zurich Hosp, Med Clin Res Unit B, Dept Med, Ramistr 100, CH-8091 Zurich, Switzerland Univ Zurich Hosp Ramistr 100 Zurich Switzerland CH-8091 rland
Citazione:
R. Walter et al., "Tetrahydrobiopterin increases myocardial blood flow in healthy volunteers:a double-blind, placebo-controlled study", SWISS MED W, 131(7-8), 2001, pp. 91-94

Abstract

Objectives: Tetrahydrobiopterin (BH4) is a regulatory cofactor for the activity of nitric oxide synthases. Vasodilating properties of BH4 have been reported in vitro and in vivo. The influence of BH4 on myocardial blood flow(MBF), however, is largely unknown. We therefore performed a double-blind,placebo-controlled study to investigate the effect of intravenous BH4 on MBF in healthy volunteers. Methods and Results: Resting MBF was assessed in 15 subjects receiving either intravenous BH4 (10 mg/kg) or placebo using positron emission tomography (PET) and [N-13]ammonia. From a mean baseline MBF of 0.91 +/- 0.09 ml/min/g, MBF increased to 1.18 +/- 0.10 ml/min/g after BH4 (n = 10; p = 0.0042). In contrast, in the group receiving placebo mean MBF remained unchanged (non-significant decrease from 0.97 +/- 0.19 to 0.84 +/- 0.11 ml/min/g; n = 5; p = 0.36). Systemic haemodynamics and ECGs remained unaffected in both groups. BH4 was very well tolerated. Conclusion: Systemically administered BH4 is safe and effectively increases resting MBF in health volunteers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/02/20 alle ore 17:16:38